ReviewCNS drug reviews2002
Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.
Review in CNS drug reviews, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 48 citations in OpenAlex.
- Comparing affective bias modification by first- and second-generation antidepressants in male rats using a translational behavioural task.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Impact of COVID- 19 pandemic on antidepressants consumptions by wastewater analysis in Turkey.The Science of the total environment · 2022Article
- Novel Pharmacological Approaches to the Treatment of Depression.Life (Basel, Switzerland) · 2022Review
- Synthesis and Biological Evaluation of Dantrolene-Like Hydrazide and Hydrazone Analogues as Multitarget Agents for Neurodegenerative Diseases.ChemMedChem · 2021Article
- Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Review
- Palladium nanoparticles on a pyridinium supported ionic liquid phase: a recyclable and low-leaching palladium catalyst for aminocarbonylation reactions.RSC advances · 2020Article
- A Prospective Repurposing of Dantrolene as a Multitarget Agent for Alzheimer's Disease.Molecules (Basel, Switzerland) · 2019Article
- Kinetics, mechanism, and inhibition of monoamine oxidase.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.Trends in pharmacological sciences · 2016Review
- Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.British journal of clinical pharmacology · 2009Article
- Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.Drug safety · 2009Review
- Moclobemide: therapeutic use and clinical studies.CNS drug reviews · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The benzamide moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA). It has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively in anxiety disorders. While clinical aspects will be presented in a subsequent review, this article focuses primarily on moclobemide's evolution, pharmacodynamic and pharmacokinetic properties. In particular, the effects on neurotransmission and intracellular signal transduction, the neuroendocrine system, the tyramine pressure response and animal models of depression are surveyed. In addition, other CNS effects are reviewed with special respect to experimental serotonergic syndrome, anxiolytic and antinociceptive activity, sleep, cognition and driving performance, neuroprotection and seizures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.